Fig. 2: The adaptive immune system is required for IV BCG antitumoral efficacy. | Nature Communications

Fig. 2: The adaptive immune system is required for IV BCG antitumoral efficacy.

From: Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

Fig. 2

a Survival curve of B16-F10 tumor-bearing perforin (Perf−/−) or IFN-γ deficient (IFNγ−/−) mice treated with IV BCG at day 7, n = 11 mice for IFNγ−/− PBS IV, n = 11 for IFNγ−/− BCG IV, n = 8 for Perf−/− PBS IV, n = 6 for Perf−/− BCG IV, pooled from two independent experiments. b Survival curve of B16-F10 tumor-bearing mice receiving CD4+ or CD8+ T cell depleting antibodies and treated with IV BCG at day 7, n = 6 mice per group, from one experiment. P values were calculated using log-rank (Mantel-Cox) test (a, b). PBS phosphate-buffered saline, IV intravenous, IP intraperitoneal, WT wild-type, IFNγ interferon gamma, Perf perforin.

Back to article page